Detection of HIV-1 DNA

Details Detection of HIV-1 DNA Detection of HIV-1 DNA

1995-06-05

2003-08-26

Fredman, Jeffrey (Department: 1637)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S005000, C536S023100, C536S024300

Reexamination Certificate

active

06610476

ABSTRACT:

TECHNICAL FIELDS
This invention is in the fields of molecular biology and virology and in particular relates to human T cell leukemia virus—type III (HTLV-III).
BACKGROUND
The term human T cell leukemia-lymphoma virus (HTLV) refers to a unique family of T cell tropic retroviruses. These viruses play an important role in the pathogenesis of certain T cell neoplasms. There are presently three known types of HTLVs. One subgroup of the family, HTLV-type I (HTLV-I), is linked to the cause of adult T-cell leukemia-lymphoma (ATLL) that occurs in certain regions of Japan, the Caribbean and Africa. HTLV-type II (HTLV-II) has been isolated from a patient with a T-cell variant of hairy cell leukemia. M. Popovic et al., Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS.
Science
, 224:497-500 (1984).
HTLV-type III (HTLV-III) has been isolated from many patients with acquired immunodeficiency syndrome (AIDS). HTLV-III refers to prototype virus isolated from AIDS patients. Groups reported to be at greatest risk for AIDS include homosexual or bisexual males; intravenous drug users and Haitian immigrants to the United States. Hemophiliacs who receive blood products pooled from donors and recipients of multiple blood transfusions are also at risk. Clinical manifestations of AIDS include severe, unexplained immune deficiency which generally involves a depletion of helper T lymphocytes. These may be accompanied by malignancies and infections. The mortality rate for patients with AIDS is high. A less severe form of AIDS also exists, in which there may be lymphadenopathy and depressed helper T cell counts; there is not, however, the devastating illness characteristic of full-blown AIDS. There are many individuals, who are classified as having early AIDS (pre-AIDS), who exhibit these signs. It is not now possible to predict who among them will develop the more serious symptoms.
Much of the evidence implicates HTLV-III as the etiological agent of the infectious AIDS. First, there is consistent epidemiology; greater than 95% of the patients with AIDS have antibodies specific for HTLV-III. Second, there has been reproducible identification and isolation of virus in this disease; more than 100 variants of HTLV-III have been isolated from AIDS patients. Third, there has been transmission of the disease to normal healthy individuals who received blood transfusions from infected blood donors.
HTLV-III has been shown to share several properties with HTLV-I and HTLV-II but also to be morphologically, biologically and antigenically distinguishable. R. C. Gallo et al., Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and At Risk for AIDS.
Science
, 224:500-503. (1984). For example, HTLV-III has been shown to be antigenically related to HTLV-I and HTLV-II by demonstrating cross-reactivity with antibodies to HTLV-I and HTLV-II core proteins, p24 and p19, and envelope antigens and by nucleic acid cross-hybridization studies with cloned HTLV-I and HTLV-II DNAs. However, unlike HTLV-I and HTLV-II, it lacked the ability to infect and transform T cells from normal umbilical cord blood and bone marrow in vitro, and has the cytopathic effect on infected cells only.
Like the RNA genome of other retroviruses, the RNA genome of HTLV-III contains three genes which encode viral proteins: 1) the gag gene, which encodes the internal structural (nucleocapsid or core) proteins; 2) the pol gene, which encodes the RNA-directed DNA polymerase (reverse transcriptase); and 3) the env gene, which encodes the envelope glycoproteins of the virion. In addition, the HTLV-III genome contains a region designated Px, located between the env gene and the 3′ LTR, which appears to be involved in functional killing of the virus.
At this time, AIDS is still difficult to diagnose before the onset of clinical manifestations. There is no method presently available for the prevention of the disease. Treatment of those with AIDS is generally not successful and victims succumb to the devastating effects HTLV-III has on the body.
SUMMARY OF THE INVENTION
This invention is based upon applicant's cloning of HTLV-III DNA in recombinant/vector host systems capable of expressing immunoreactive HTLV-III polypeptides. Based on the cloning of HTLV-III DNA in systems which express immunoreactive-polypeptides, applicant has developed methods useful in the diagnosis, treatment and prevention of AIDS. Applicant has developed methods of detecting HTLV-III and antibodies against HTLV-III in body fluids (e.g., blood, saliva, semen), and methods useful in immunotherapy (e.g., vaccination and passive immunization against AIDS). In addition, applicant has developed methods of making HTLV-III DNA probes and RNA probes useful in detecting HTLV-III in body fluids.
Polypeptides encoded by segments of the HTLV-III genome have been produced by these recombinant DNA methods. For example, polypeptides encoded by three regions of the HTLV-III genome (an env gene sequence, an env-lor gene sequence and a 1.1 Kb EcoRI restriction fragment from HTLV-III cDNA) have been produced. The polypeptides expressed have been isolated. These polypeptides are immunoreactive with sera of patients having AIDS and with antibodies to HTLV-III and thus are useful in screening blood and other body fluids for the presence of antibodies against HTLV-III. Applicant's invention therefore provides a method not only for diagnosing AIDS, but also for preventing the transmission of the disease to others through blood or blood components harboring HTLV-III. The latter is particularly valuable in screening donated blood before it is transfused or used to obtain blood components (e.g., Factor VIII for the treatment of hemophilia; Factor IX)
Polypeptides produced by the recombinant DNA methods are employed in the production of antibodies, including monoclonal antibodies, against the virus. Such antibodies form the basis for immunoassay and diagnostic techniques for directly detecting HTLV-III in body fluids such as blood, saliva, semen, etc. Neutralizing antibodies against the virus may be used to passively immunize against the disease.
Applicant's cloning of HTLV-III DNA in such recombinant vector host systems also provides the basis for determination of the nucleotide sequence of HTLV-III DNA. The DNA probes are homologous to DNA regions which are unique to the HTLV-III genome. DNA probes provide another method of detecting HTLV-III in blood, saliva or other body fluids. RNA probes which contain regions unique to the HTLV-III genome can also be formed and used for the detection of HTLV-III in body fluids.


REFERENCES:
patent: 4520113 (1985-05-01), Gallo
patent: 4689398 (1987-08-01), Wu
patent: 4708818 (1987-11-01), Montagnier
patent: 4716102 (1987-12-01), Levy
patent: 4725669 (1988-02-01), Essex
patent: 5135864 (1992-08-01), Montagnier
McGrath et al, “Using HIV-1 sequence variability to explore virus biology”, Virus Research (2001) 76:137-160.*
Chiron Corporation v. Abbott Laboratories, 902 F.Supp. 1103, 1130 (N.D.Cal. 1995).
Settlement Agreement and Stipulation for Dismissal and Order dated Aug. 27, 1996.
Declaration of John A.T. Young, Ph.D. (Declaration Exhibit 1 LUCIW, Interference No. 103,659).
Expert Report of Robin A. Weiss, Ph.D., dated Apr. 17, 1995 (Declaration Exhibit 46 LUCIW, Interference No. 103,659).
Declaration of Robin A. Weiss, Ph.D., dated Feb. 15, 1996 (Declaration Exhibit 2 LUCIW, Interference No. 103,659).
Declaration of William Robinson, M.D. (Declaration Exhibit 3 LUCIW, Interference No. 103,659).
Anilonis, A., et al., Structure of the glycoprotein gene in rabies virus.Nature294: 275-278 (1981).
Arya, S.K., et al., Homology of genome of AIDS-associated virus with genomes of human T-cell leukemia viruses.Science225:927-929 (1984).
Ghrayeb, J., et al., Secretion cloning vectors inEscherichia coli, EMBO J., 3:2437-2442 (1984).
Gray, M.R., et al., Open reading frame cloning: Identification, cloning, and expression of open reading frame DNA,Proc. Nat

Affiliated with

Also associated with

Rating

Detection of HIV-1 DNA does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Detection of HIV-1 DNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of HIV-1 DNA will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3085807